Plasma levels of tissue inhibitor of matrix metalloproteinase-1 correlate with diagnosis and prognosis of glioma patients
查看参考文献24篇
|
文摘
|
Background There is no validated blood biomarker available for glioma management. Invasive growth is the key feature of glioma. We assessed the clinical usefulness of plasma tissue inhibitor of metalloproteinase 1 (TIMP-1), which has less molecular weight than metalloproteinases, as a potential blood biomarker for glioma. Methods A total of 285 patients and 59 normal subjects were studied. Plasma concentration of TIMP-1 was measured with enzyme-linked immunosorbent assay. Plasma TIMP-1 was compared between normal and glioma patients, between patients with different pathological grades, and between patients with different prognoses. Longitudinal changes in plasma TIMP-1 during treatment were also evaluated. Plasma matrix metalloproteinase (MMP)-9 level was also assayed and its clinical usefulness was compared with that of TIMP-1. Results Plasma TIMP-1 and MMP-9 were both increased in glioma patients compared with normal controls (TIMP-1: P <0.001; MMP-9: P=0.007). Plasma TIMP-1 increases with increased tumor grade. In Grade IV gliomas, plasma TIMP-1 significantly increased after “successful removal” of the tumor (paired samples t-test, before operation vs. during chemotherapy without recurrence, t = –2.131, P=0.038), but did not change significantly at the time of tumor recurrence (during chemotherapy without recurrence vs. after tumor recurrence, t = –0.652, P=0.632). High plasma TIMP-1 level correlated with better survival in Grade IV glioma patients (hazard ratio: 0.550, 95% CI: 0.101–1.000, P=0.036). In Grade IV gliomas, patients with higher plasma TIMP-1 had significantly longer survival time than those with lower plasma TIMP-1 level (25.23 vs. 18.95 months, log-rank P=0.045). Plasma MMP-9 did not show significant association with either the pathological grade or the prognosis of glioma patients. Conclusions Plasma TIMP-1 is associated with the diagnosis and prognosis of glioma patients. It appears to have better usefulness for guiding clinical decision making than plasma MMP-9. Further studies in an expanded patient population are needed to better define its clinical usefulness. |
|
来源
|
Chinese Medical Journal
,2013,126(22):4295-4300 【核心库】
|
|
DOI
|
10.3760/cma.j.issn.0366-6999.20131765
|
|
关键词
|
glioma
;
plasma
;
biomarker
;
tissue inhibitor of metalloproteinase 1
;
metalloproteinase 9
|
|
地址
|
1.
Department of Neurosurgery, First Hospital of China Medical University, Liaoning, Shenyang, 110001
2.
Department of Neurosurgery, Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100050
3.
Harvard Medical School, USA, Boston
|
|
语种
|
英文 |
|
文献类型
|
研究性论文 |
|
ISSN
|
0366-6999 |
|
学科
|
医药、卫生 |
|
基金
|
国家自然科学基金
;
国家863计划
;
International Science and Technology Cooperation Program
|
|
文献收藏号
|
CSCD:4983975
|
参考文献 共
24
共2页
|
|
1.
James C D. Molecular biology of central nervous system tumors.
Cancer: principles and practice of oncology, 9th ed,2011:1692-1699
|
CSCD被引
1
次
|
|
|
|
|
2.
Rivera A L. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.
Neuro Oncol,2010,12:116-121
|
CSCD被引
10
次
|
|
|
|
|
3.
Giannini C. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402.
Brain Pathol,2008,18:360-369
|
CSCD被引
5
次
|
|
|
|
|
4.
Houillier C. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.
Neurology,2010,75:1560-1566
|
CSCD被引
21
次
|
|
|
|
|
5.
Rees J H. Diagnosis and treatment in neuro-oncology: an oncological perspective.
Br J Radiol,2011,84(Spec No 2):S82-S89
|
CSCD被引
3
次
|
|
|
|
|
6.
Iwamoto F M. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.
Neuro Oncol,2011,13:1244-1251
|
CSCD被引
4
次
|
|
|
|
|
7.
Liu B L. Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas.
Neuro Oncol,2010,12:540-548
|
CSCD被引
9
次
|
|
|
|
|
8.
Iwadate Y. High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas.
Anticancer Res,2008,28:415-418
|
CSCD被引
2
次
|
|
|
|
|
9.
Todaro L. Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors.
J Neurooncol,2007,83:135-144
|
CSCD被引
2
次
|
|
|
|
|
10.
Fukuda M E. Cathepsin D is a potential serum marker for poor prognosis in glioma patients.
Cancer Res,2005,65:5190-5194
|
CSCD被引
5
次
|
|
|
|
|
11.
Lin Y. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas.
Neuro Oncol,2009,11:468-476
|
CSCD被引
4
次
|
|
|
|
|
12.
Elstner A. Identification of diagnostic serum protein profiles of glioblastoma patients.
J Neurooncol,2011,102:71-80
|
CSCD被引
3
次
|
|
|
|
|
13.
Lin Y. Increase of plasma IgE during treatment correlates with better outcome of patients with glioblastoma.
Chin Med J,2011,124:3042-3048
|
CSCD被引
2
次
|
|
|
|
|
14.
Lin Y. A panel of four cytokines predicts the prognosis of patients with malignant gliomas.
J Neurooncol,2013,114:199-208
|
CSCD被引
1
次
|
|
|
|
|
15.
Matsukado Y. The growth of glioblastoma multiforme (astrocytomas, grades 3 and 4) in neurosurgical practice.
J Neurosurg,1961,18:636-644
|
CSCD被引
1
次
|
|
|
|
|
16.
Bell E Jr. Cerebral hemispherectomy; report of a case 10 years after operation.
J Neurosurg,1949,6:285-293
|
CSCD被引
1
次
|
|
|
|
|
17.
Clark I M. The regulation of matrix metalloproteinases and their inhibitors.
Int J Biochem Cell Biol,2008,40:1362-1378
|
CSCD被引
32
次
|
|
|
|
|
18.
Sato H. Coordinate action of membrane-type matrix metalloproteinase-1 (MT1-MMP) and MMP-2 enhances pericellular proteolysis and invasion.
Cancer Sci,2010,101:843-847
|
CSCD被引
13
次
|
|
|
|
|
19.
Nakano A. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas.
J Neurosurg,1995,83:298-307
|
CSCD被引
9
次
|
|
|
|
|
20.
Forsyth P A. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas.
Br J Cancer,1999,79:1828-1835
|
CSCD被引
19
次
|
|
|
|
|
了解气象卫星更多信息，请访问